Trial intelligence / Profile preview

HEC53856 in Renal Anemia on Dialysis

NCT04925674Phase 1Completed

Sponsor
Sunshine Lake Pharma
Start
Sep 2021
Primary completion
Oct 2022
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, open-label trial of HEC53856 in anemia of chronic kidney disease (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Incidence of Adverse Events. Started Sep 2021; status: completed.

02

Drugs

HEC53856
03

Conditions

anemia of chronic kidney disease

Beyond the preview

Go deeper on NCT04925674.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04925674.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call